We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic Company Acquisition to Ease Market Entry and Shorten Development Time for New Tests

By LabMedica International staff writers
Posted on 15 Sep 2015
Two North American manufacturers of rapid diagnostic tests are combining in order to pool their products for rapid entry into the diagnostic product market and to boost development of new tests.

NOWDiagnostics Inc. More...
(Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada). NOWDiagnostics manufactures and sells a line of blood-based rapid tests that allow health care providers to conduct simple-to-use, highly accurate tests for a variety of ailments and diseases. ZBx Corporation, with a customer base that includes Canada, Europe, Asia, Africa, South America and Mexico, develops and manufactures rapid format, point-of-care diagnostic products in both the human and veterinary fields.

“We are excited about the growth of NOWDiagnostics and what this means for point-of-care testing and the healthcare industry in general. Our acquisition of ZBx, with its deep product portfolio, experienced personnel, and broad capabilities, will help us increase the speed at which we are currently developing our tests,” said Kevin Clark, CEO of NOWDiagnostics. “The tests we are creating have the potential to revolutionize current medical test protocols and to lower costs to insurance companies and, ultimately, consumers.”

Related Links:

NOWDiagnostics
ZBx Corporation



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer

Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: Benchmarking design for systematic evaluation of PASEF acquisition strategies (Xian, F., Mitulovic, G., Ravi Kumar, R.K. et al.  Nature Communications. https://doi.org/10.1038/s41467-026-75845-5)

Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation

The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.